



March 19, 2018

Karen Rogers , Acting Director
Office of Technology Transfer
National Institutes of Health
rogersk@mail.nih.gov

Jill Roering, Acting Deputy Director
Office of Technology Transfer
National Institutes of Health
roeringj@mail.nih.gov

Bruce Goldstein, JD, MS , Assistant Director, Monitoring & Enforcement,
Office of Technology Transfer
National Institutes of Health
goldsteb@mail.nih.gov

Dear Karen Rogers, Jill Roering and Bruce Goldstein:

I am forwarding a memorandum that describes six patents granted to Daniel J Rader and assigned to the Trustees of the University of Pennsylvania, each with the same title:

Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects.

All six patents are listed in the FDA Orange Book for the drug Juxtapid. None of the six patents disclose federal funding. We believe all six patents were based upon research funded by the NIH, including but not limited to 4 NIH projects that include in their title "BMS-201038," the name of the compound now known as Juxtapid.

The memorandum provides more details on the relationship between the six patents and the four grants, and asks the NIH to take title to the patents as a remedy for the failure by Daniel Rader to acknowledge the NIH funding in the patent application.

We were surprised that the University of Pennsylvania, which received more than \$68 million in grants from the NIH for which Daniel J. Rader was the principal investigator, failed to disclose the NIH funding in the patent application as required by law.

Sincerely,

A handwritten signature in blue ink, appearing to read "Andrew S. Goldman".

Andrew S. Goldman, Esq.
Counsel, Policy and Legal Affairs
andrew.goldman@keionline.org

A handwritten signature in blue ink, appearing to read "James Love".

James Love, Director, KEI
james.love@keionline.org
+1.202.332.2670

Cc: The Honorable Daniel R. Levinson, Dan.Levinson@oig.hhs.gov